Genicular Artery Embolization: A Revolutionary Approach to Knee Pain in Reston, VA

The Knee Pain Treatment Gap: Millions of Patients Left in Between

Knee osteoarthritis (OA) affects roughly 16% of the global population and is one of the leading causes of disability in adults over 50. For many patients, the disease follows a frustrating trajectory: physical therapy and anti-inflammatory medications provide initial relief, but over time the pain worsens and these conservative measures lose effectiveness. At that point, the traditional next step has been total knee replacement—a major surgery with months of rehabilitation.

But what about the millions of patients who fall in between? Those whose knee pain is too severe for over-the-counter remedies yet who are not ready for—or are not good candidates for—joint replacement surgery? In the United States alone, this population was estimated at 3.6 million people and projected to reach 5 million by 2025 (van Zadelhoff et al., Annals of the Rheumatic Diseases, 2024).

Genicular artery embolization (GAE) is a minimally invasive procedure now available at SAC’s Reston, Virginia office that addresses this critical treatment gap.

What Is Genicular Artery Embolization?

GAE is a catheter-based, image-guided procedure performed by an interventional radiologist. It targets the abnormal blood vessels (neovascularization) that develop in the inflamed synovial lining of osteoarthritic knees. These abnormal vessels are accompanied by nerve fibers that become sensitized to pain. By selectively blocking these vessels with tiny microscopic particles, GAE reduces inflammation, suppresses abnormal nerve signaling, and provides significant pain relief—all without a single surgical incision.

The procedure is performed under moderate sedation through a small puncture in the femoral artery (at the upper thigh). Using fluoroscopic guidance, the interventional radiologist navigates a microcatheter to the genicular arteries around the knee, identifies areas of abnormal vascular blush on angiography, and delivers embolic microspheres to block those targeted vessels. The entire procedure typically takes 60 to 90 minutes, and patients go home the same day.

What Does the Research Say?

Two-Year IDE Trial Results (UCLA, 2024)

The most rigorous evidence for GAE comes from a prospective Investigational Device Exemption (IDE) trial at UCLA, published in the Journal of Vascular and Interventional Radiology in September 2024. In this study of 40 patients with moderate-to-severe knee OA, 47.4% achieved at least a 50% reduction in WOMAC scores (a validated measure of knee pain, stiffness, and function) at 24 months. Among patients who demonstrated initial success at 12 months, 72% maintained that improvement through the two-year mark (Cusumano et al., JVIR, 2024).

GENESIS Trial: Long-Term UK Results (2024)

The GENESIS trial, published in Cardiovascular and Interventional Radiology in 2024, followed 46 patients with mild-to-moderate knee OA after GAE with permanent microspheres. The study reported sustained improvements in both pain scores (VAS) and knee function (KOOS) at two years, with technical success in 100% of cases and only mild, transient adverse events such as temporary skin warmth near the knee (Little et al., Cardiovasc Intervent Radiol, 2024).

Meta-Analysis: Consistent Results Across Studies

A systematic review and meta-analysis published in the Journal of Clinical Medicine encompassing 9 studies and 270 patients found that GAE achieved 99.7% technical success with significant pain reduction at every follow-up interval through 12 months. Weighted mean pain VAS improvements ranged from 34 to 39 points (on a 100-point scale), well exceeding the threshold for clinically meaningful improvement. At two years, the total knee replacement rate was only 5.2% and the repeat GAE rate was 8.3% (Talaie et al., J Clin Med, 2023).

2025 Biomarker Trial: Evidence of Disease Modification

A 2025 prospective trial published in JVIR provided the first biomarker evidence that GAE may do more than just relieve symptoms—it may modify the underlying disease process. Researchers found that GAE was associated with significant reductions in vascular endothelial growth factor (VEGF) and interleukin-1 receptor antagonist (IL-1RA) at 12 months, suggesting that the procedure suppresses the abnormal angiogenesis and inflammation driving osteoarthritis pain (JVIR, 2025).

Key Takeaway from the Research
GAE consistently shows durable pain relief lasting one to two or more years in patients with mild-to-moderate knee OA who have failed conservative therapy. It is a same-day, outpatient procedure with a near-perfect technical success rate and a safety profile limited to mild, temporary side effects. While still considered an emerging therapy, the evidence base is growing rapidly and now includes prospective trials, randomized controlled trials, and meta-analyses.

Who Is a Good Candidate for GAE?

GAE may be right for you if you meet the following criteria:

You have mild-to-moderate knee osteoarthritis (typically Kellgren-Lawrence grade 2 or 3 on X-ray). The strongest evidence supports GAE in this population. Patients with severe, bone-on-bone arthritis (KL grade 4) generally benefit more from total knee replacement.

Conservative treatments have stopped working. You have tried physical therapy, anti-inflammatory medications, corticosteroid injections, or viscosupplementation (gel injections) for at least three months without adequate relief.

You are not ready for or cannot have knee replacement surgery. Whether due to age, medical conditions, personal preference, or wanting to delay surgery, GAE offers a bridge option that does not burn any bridges—you can still have knee replacement later if needed.

You want a minimally invasive, same-day procedure. GAE requires no general anesthesia, no surgical incision, and no hospital stay. Most patients resume normal activities within days.

What to Expect: The GAE Experience at SAC Reston

Before the procedure: You will have a consultation with our interventional team at our Reston office, including a review of your knee imaging (X-rays and/or MRI), medical history, and treatment goals. We will explain the procedure in detail and answer all of your questions.

During the procedure: GAE is performed in our office-based vascular suite under moderate sedation. A small catheter is inserted through a tiny puncture (no incision) and guided to the knee’s blood supply using real-time imaging. The procedure typically takes 60 to 90 minutes. You remain comfortable throughout.

After the procedure: You will rest briefly in our recovery area and go home the same day. Some patients notice temporary warmth or mild discomfort around the knee for a few days. Most return to normal activities within two to three days. Pain relief typically begins within the first few weeks and continues to improve over one to three months as inflammation subsides.

Why Choose SAC in Reston for GAE?

Located in the heart of Northern Virginia, our Reston office provides convenient access to GAE for patients throughout Fairfax County, Loudoun County, and the greater Washington, DC metropolitan area. Our interventional radiology team combines advanced training in embolization techniques with a patient-centered approach—meaning your treatment plan is built around your goals, not a one-size-fits-all protocol.

SAC’s office-based vascular suites are equipped with state-of-the-art fluoroscopic imaging, allowing us to perform GAE in a comfortable, private setting without the overhead, scheduling delays, and exposure risks of a hospital operating room. We accept most major insurance plans, and our team will work with you on coverage verification.

If chronic knee pain has been holding you back from the activities you love, and you want to explore a cutting-edge alternative to surgery, contact SAC’s Reston office today to schedule your GAE consultation.